Literature DB >> 22589485

Epigenetic changes in pediatric solid tumors: promising new targets.

Elizabeth R Lawlor1, Carol J Thiele.   

Abstract

Cancer is being reinterpreted in the light of recent discoveries related to the histone code and the dynamic nature of epigenetic regulation and control of gene programs during development, as well as insights gained from whole cancer genome sequencing. Somatic mutations in or deregulated expression of genes that encode chromatin-modifying enzymes are being identified with high frequency. Nowhere is this more relevant than in pediatric embryonal solid tumors. A picture is emerging that shows that classic genetic alterations associated with these tumors ultimately converge on the epigenome to dysregulate developmental programs. In this review, we relate how alterations in components of the transcriptional machinery and chromatin modifier genes contribute to the initiation and progression of pediatric solid tumors. We also discuss how dramatic progress in our understanding of the fundamental mechanisms that contribute to epigenetic deregulation in cancer is providing novel avenues for targeted cancer therapy. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589485      PMCID: PMC3691809          DOI: 10.1158/1078-0432.CCR-11-1921

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  103 in total

1.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

Authors:  Chunxi Wang; Zhihui Liu; Chan-Wook Woo; Zhijie Li; Lifeng Wang; Jun S Wei; Victor E Marquez; Susan E Bates; Qihuang Jin; Javed Khan; Kai Ge; Carol J Thiele
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

Review 2.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

3.  Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner.

Authors:  Hongjuan Cui; Jun Ma; Jane Ding; Tai Li; Goleeta Alam; Han-Fei Ding
Journal:  J Biol Chem       Date:  2006-09-18       Impact factor: 5.157

4.  Coordinated regulation of polycomb group complexes through microRNAs in cancer.

Authors:  Qi Cao; Ram-Shankar Mani; Bushra Ateeq; Saravana M Dhanasekaran; Irfan A Asangani; John R Prensner; Jung H Kim; J Chad Brenner; Xiaojun Jing; Xuhong Cao; Rui Wang; Yong Li; Arun Dahiya; Lei Wang; Mithil Pandhi; Robert J Lonigro; Yi-Mi Wu; Scott A Tomlins; Nallasivam Palanisamy; Zhaohui Qin; Jindan Yu; Christopher A Maher; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

5.  Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?

Authors:  R L Stallings; J Howard; A Dunlop; M Mullarkey; M McDermott; F Breatnach; A O'Meara
Journal:  Cancer Genet Cytogenet       Date:  2003-01-15

6.  Downstream EWS/FLI1 - upstream Ewing's sarcoma.

Authors:  Heinrich Kovar
Journal:  Genome Med       Date:  2010-01-28       Impact factor: 11.117

7.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

8.  Prevalence and functional consequence of PHOX2B mutations in neuroblastoma.

Authors:  E H Raabe; M Laudenslager; C Winter; N Wasserman; K Cole; M LaQuaglia; D J Maris; Y P Mosse; J M Maris
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

9.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

Review 10.  Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.

Authors:  R Gupta; R Webb-Myers; S Flanagan; M E Buckland
Journal:  J Clin Pathol       Date:  2011-07-12       Impact factor: 4.463

View more
  48 in total

Review 1.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

2.  Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.

Authors:  Laurie K Svoboda; Ashley Harris; Natashay J Bailey; Raphaela Schwentner; Eleni Tomazou; Cornelia von Levetzow; Brian Magnuson; Mats Ljungman; Heinrich Kovar; Elizabeth R Lawlor
Journal:  Epigenetics       Date:  2014-12       Impact factor: 4.528

3.  Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.

Authors:  Veronica Veschi; Zhihui Liu; Ty C Voss; Laurent Ozbun; Berkley Gryder; Chunhua Yan; Ying Hu; Anqi Ma; Jian Jin; Sharlyn J Mazur; Norris Lam; Barbara K Souza; Giuseppe Giannini; Gordon L Hager; Cheryl H Arrowsmith; Javed Khan; Ettore Appella; Carol J Thiele
Journal:  Cancer Cell       Date:  2017-01-09       Impact factor: 31.743

Review 4.  Developmental origins and oncogenic pathways in malignant brain tumors.

Authors:  Q Richard Lu; Lily Qian; Xianyao Zhou
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2019-04-03       Impact factor: 5.814

Review 5.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

6.  Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.

Authors:  Bárbara Kunzler Souza; Patrícia Luciana da Costa Lopez; Pâmela Rossi Menegotto; Igor Araujo Vieira; Nathalia Kersting; Ana Lúcia Abujamra; André T Brunetto; Algemir L Brunetto; Lauro Gregianin; Caroline Brunetto de Farias; Carol J Thiele; Rafael Roesler
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

Review 7.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.

Authors:  Roberta Ciarapica; Elena Carcarino; Laura Adesso; Maria De Salvo; Giorgia Bracaglia; Pier Paolo Leoncini; Alessandra Dall'agnese; Federica Verginelli; Giuseppe M Milano; Renata Boldrini; Alessandro Inserra; Stefano Stifani; Isabella Screpanti; Victor E Marquez; Sergio Valente; Antonello Mai; Pier Lorenzo Puri; Franco Locatelli; Daniela Palacios; Rossella Rota
Journal:  BMC Cancer       Date:  2014-02-27       Impact factor: 4.430

Review 9.  Management of familial cancer: sequencing, surveillance and society.

Authors:  Nardin Samuel; Anita Villani; Conrad V Fernandez; David Malkin
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

10.  The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.

Authors:  J K Parrish; M Sechler; R A Winn; P Jedlicka
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.